Migraine: emerging treatment options for preventive and acute attack therapy

Bibliography

• LIPTON RB, STEWART WF, DIAMOND S, DIAMOND ML, REED M: Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache (2001) 41:646-657.
   PubMed Web of Science ®Google Scholar
• MENKEN M, MUNSAT TL, TOOLE JF: The global burden of disease study – implications for neurology. Arch. Neurol. (2000) 57:418-420.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, LIPTON RB, FERRARI MD: Migraine – current understanding and treatment. N. Engl. J. Med. (2002) 346:257-270.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ: Pathophysiology of migraine. In: Migraine and Other Headache Disorders. RB Lipton, M Bigal (Eds), Marcel Dekker, Taylor & Francis Books, Inc, New York, US (2006):81-98.
   Google Scholar
• ANDLIN-SOBOCKI P, JONSSON B, WITTCHEN HU, OLESEN J: Cost of disorders of the brain in Europe. Eur. J. Neurol. (2005) 12(Suppl. 1):1-27.
   PubMed Web of Science ®Google Scholar
• STEWART WF, RICCI JA, CHEE E, MORGANSTEIN D, LIPTON R: Lost productive time and cost due to common pain conditions in the US workforce. JAMA (2003) 290:2443-2454.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, FERRARI MD: Headache. In: The Neurobiology of Pain. SP Hunt, M Koltzenburg (Eds), Oxford University Press, Oxford, UK (2005):333-374.
   Google Scholar
• OLESEN J, TFELT-HANSEN P, RAMADAN N, GOADSBY PJ, WELCH KMA: The Headaches. Lippincott, Williams & Wilkins, Philadelphia, US (2005).
   Google Scholar
• HEADACHE CLASSIFICATION COMMITTEE OF THE INTERNATIONAL HEADACHE SOCIETY: The International Classification of Headache Disorders (second edition). Cephalalgia (2004) 24(Suppl. 1):1-160.
   Web of Science ®Google Scholar
• LANCE JW, GOADSBY PJ: Mechanism and Management of Headache, 7th edn. Elsevier, New York, US (2005).
   Google Scholar
• GOADSBY PJ: Can we develop neurally-acting drugs for the treatment of migraine? Nat. Rev. Drug Discov. (2005) 4:741-750.
   PubMed Web of Science ®Google Scholar
• STEWART WF, LIPTON RB, WHYTE J et al.: An international study to assess reliability of the Migraine Disability Assessment (MIDAS) score. Neurology (1999) 53:988-994.
   PubMed Web of Science ®Google Scholar
• BJORNER JB, KOSINSKI M, WARE JE Jr: Calibration of an item pool for assessing the burden of headaches: an application of item response theory to the headache impact test (HIT). Qual. Life Res. (2003) 12:913-933.
   PubMed Web of Science ®Google Scholar
• LIPTON RB, STEWART WF, SAWYER J, EDMEADS JG: Clinical utility of an instrument assessing migraine disability: the migraine disability assessment (MIDAS) questionnaire. Headache (2001) 41:854-861.
   PubMed Web of Science ®Google Scholar
• SILBERSTEIN SD, LIPTON RB, GOADSBY PJ: Headache in Clinical Practice, 2nd edn. Martin Dunitz, London, UK (2002).
   Google Scholar
• DODICK D, LIPTON RB, MARTIN V et al.: Consensus statement: cardiovascular safety profile of triptans (5-HT1B/1D agonists) in the acute treatment of migraine. Headache (2004) 44:414-425.
   PubMed Web of Science ®Google Scholar
• LIPTON RB, LIBERMAN J, CUTRER FM et al.: Treatment preferences and the selection of acute migraine medications: results from a population-based survey. Journal of Headache and Facial Pain (2004) 5:123-130.
   Google Scholar
• GOADSBY PJ, DODICK D, FERRARI MD, MCCRORY D, WILLIAMS P: TRIPSTAR. Prioritizing triptan treatment attributes in migraine management. Acta Neurologica Scandinavica (2004) 110:137-143.
   PubMed Web of Science ®Google Scholar
• FERRARI MD, GOADSBY PJ, LIPTON RB et al.: The use of multiattribute decision models in evaluating triptan treatment options in migraine. J. Neurol. (2005) 252:1026-1032.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ: The pharmacology of headache. Prog. Neurobiol. (2000) 62:509-525.
   PubMed Web of Science ®Google Scholar
• FERRARI MD, GOADSBY PJ, ROON KI, LIPTON RB: Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia (2002) 22:633-658.
   PubMed Web of Science ®Google Scholar
• HUMPHREY PPA, FENIUK W, PERREN MJ, BERESFORD IJM, SKINGLE M, WHALLEY ET: Serotonin and migraine. Ann. NY Acad. Sci. (1990) 600:587-598.
   PubMed Web of Science ®Google Scholar
• MOSKOWITZ MA, CUTRER FM: SUMATRIPTAN: a receptor-targeted treatment for migraine. Ann. Rev. Med. (1993) 44:145-154.
   PubMed Web of Science ®Google Scholar
• SELBY G, LANCE JW: Observations on 500 cases of migraine and allied vascular headache. J. Neurol. Neurosurg. Psychiat. (1960) 23:23-32.
   PubMed Web of Science ®Google Scholar
• BURSTEIN R, JAKUBOWSKI M: Analgesic triptan action in an animal model of intracranial pain: a race against the development of central sensitisation. Ann. Neurol. (2004) 55:27-36.
   PubMed Web of Science ®Google Scholar
• SHIELDS KG, GOADSBY PJ: Serotonin receptors modulate trigeminovascular responses in ventroposteromedial nucleus of thalamus: a migraine target? Neurobiol. Dis. (2006) (In Press).
   PubMedGoogle Scholar
• BARTSCH T, KNIGHT YE, GOADSBY PJ: Activation of 5-HT1B/1D receptors in the periaqueductal grey inhibits meningeal nociception. Ann. Neurol. (2004) 56:371-381.
   PubMed Web of Science ®Google Scholar
• SHIELDS KG, GOADSBY PJ: Propranolol modulates trigeminovascular responses in thalamic ventroposteromedial nucleus: a role in migraine? Brain (2005) 128:86-97.
   PubMed Web of Science ®Google Scholar
• STORER RJ, GOADSBY PJ: Topiramate inhibits trigeminovascular neurons in the cat. Cephalalgia (2004) 24:1049-1056.
   PubMed Web of Science ®Google Scholar
• AYATA C, JIN H, KUDO C, DALKARA T, MOSKOWITZ MA: Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol. (2006) 59:652-661.
   PubMed Web of Science ®Google Scholar
• LEAO AAP: Spreading depression of activity in cerebral cortex. J. Neurophysiol. (1944) 7:359-390.
   Google Scholar
• LEAO AAP: Pial circulation and spreading activity in the cerebral cortex. J. Neurophysiol. (1944) 7:391-396.
   Google Scholar
• LAURITZEN M: Pathophysiology of the migraine aura. The spreading depression theory. Brain (1994) 117:199-210.
   PubMed Web of Science ®Google Scholar
• HADJIKHANI N, SANCHEZ DEL RIO M, WU O et al.: Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc. Natl. Acad. Sci. USA (2001) 98:4687-4692.
   PubMed Web of Science ®Google Scholar
• READ SJ, SMITH MI, HUNTER AJ, UPTON N, PARSONS AA: SB-220453, a potential novel antimigraine compound, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat. Cephalalgia (1999) 20:92-99.
   Web of Science ®Google Scholar
• SMITH MI, READ SJ, CHAN WN et al.: Repetitive cortical spreading depression in a gyrencephalic feline brain: inhibition by the novel benzoylamino-benzopyran SB-220453. Cephalalgia (2000) 20:546-553.
   PubMed Web of Science ®Google Scholar
• MAASSENVANDENBRINK A, VAN DEN BROEK RW, DE VRIES R, UPTON N, PARSONS AA, SAXENA PR: The potential anti-migraine compound SB-220453 does not contract human isolated blood vessels or myocardium; a comparison with sumatriptan. Cephalalgia (2000) 20:538-545.
   PubMed Web of Science ®Google Scholar
• PARSONS AA, BINGHAM S, RAVAL P, READ S, THOMPSON M, UPTON N: Tonabersat (SB-220453) a novel benzopyran with anticonvulsant properties attenuates trigeminal nerve-induced neurovascular reflexes. Br. J. Pharmacol. (2001) 132:1549-1557.
   PubMed Web of Science ®Google Scholar
• DIENER HC, TFELT-HANSEN P, DAHLOF C et al.: Topiramate in migraine prophylaxis-results from a placebo-controlled trial with propranolol as an active control. J. Neurol. (2004) 251:943-950.
   PubMed Web of Science ®Google Scholar
• BRANDES JL, SAPER JR, DIAMOND M et al.: Topiramate for migraine prevention: a randomized controlled trial. JAMA (2004) 291:965-973.
   PubMed Web of Science ®Google Scholar
• SILBERSTEIN SD, NETO W, SCHMITT J, JACOBS D: Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol. (2004) 61:490-495.
   PubMed Web of Science ®Google Scholar
• AKERMAN S, GOADSBY PJ: Topiramate inhibits cortical spreading depression in rat and cat: a possible contribution to its preventive effect in migraine. Cephalalgia (2004) 24:783-784.
   Google Scholar
• TVEDSKOV JF, IVERSEN HK, OLESEN J: A double-blind study of SB-220453 (Tonerbasat) in the glyceryltrinitrate (GTN) model of migraine. Cephalalgia (2004) 24:875-882.
   PubMed Web of Science ®Google Scholar
• TVEDSKOV JF, THOMSEN LL, IVERSEN HK et al.: The effect of propranolol on glyceryltrinitrate-induced headache and arterial response. Cephalalgia (2004) 24:1076-1087.
   PubMed Web of Science ®Google Scholar
• TVEDSKOV JF, THOMSEN LL, IVERSEN HK, GIBSON A, WILIAMS P, OLESEN J: The prophylactic effect of valproate on glyceryltrinitrate induced migraine. Cephalalgia (2004) 24:576-585.
   PubMed Web of Science ®Google Scholar
• SIMPSON LL: The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol. Rev. (1981) 33:155-188.
   PubMed Web of Science ®Google Scholar
• JANKOVIC J: Botulinum toxin in clinical practice. J. Neurol. Neurosurg. Psychiat. (2004) 75:951-957.
   PubMed Web of Science ®Google Scholar
• CUI M, KHANIJOU S, RUBINO J, AOKI KR: Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain (2004) 107:125-133.
   PubMed Web of Science ®Google Scholar
• AOKI KR: Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology (2005) 26:785-793.
   PubMed Web of Science ®Google Scholar
• EVERS S, RAHMANN A, VOLLMER-HAASE J, HUSSTEDT I-W: Treatment of headache with botulinum toxin A – a review according to evidence-based medicine criteria. Cephalalgia (2002) 22:699-710.
   PubMed Web of Science ®Google Scholar
• SILBERSTEIN SD, GÖBEL H, JENSEN R et al.: Botulinum toxin type A in the prophylactic treatment of chronic tension-type headache: a multicentre, double-blind, randomized, placebo-controlled, parallel-group study. Cephalalgia (2006) 26(7):790-800.
   PubMed Web of Science ®Google Scholar
• SILBERSTEIN S, MATHEW N, SAPER J, JENKINS S: Botulinum toxin type A as a migraine preventive treatment. Headache (2000) 40:445-450.
   PubMed Web of Science ®Google Scholar
• BRIN MF, SWOPE DM, O’BRIEN C, ABBASI S, PGODA JM: Botox for migraine: double-blind, placebo-controlled, region-specific evaluation. Cephalalgia (2000) 20:421-422.
   Google Scholar
• EVERS S, VOLLMER-HAASE J, SCHWAAG S, RAHMANN A, HUSSTEDT IW, FRESE A: Botulinum toxin A in the prophylactic treatment of migraine – a randomized, double-blind, placebo-controlled study. Cephalalgia (2004) 24:838-843.
   PubMed Web of Science ®Google Scholar
• RELJA M, POOLE AC, SCHOENEN J, PASCUAL J, SAULAY M, KUMAR C: A multicentre, double-blind, randomised, placebo-controlled, parallel group study of multiple treatments of botulinum toxin type A (BoNTA) for the prophylaxis of migraine headaches. J. Neurol. (2005) 252(Suppl. 2):II-62.
   Google Scholar
• SAPER JR, MATHEW NT, LODER EW, DEGRYSE R, VANDENBURGH AM: A double-blind, randomised, placebo-controlled exploratory study comparing injection sites with low doses of botulinum toxin type A in the prevention of episodic migraine. J. Neurol. (2005) 252(Suppl. 2):II-58.
   Google Scholar
• CHANKRACHANG S, ARAYAWICHANONT A, POUNGVARIN N: Botulinum toxin type A in migraine without aura prophylaxis:a 12 week prospective, multicentre, double-blin, randomized, placebo-controlled trial. Cephalalgia (2005) 25:992-993.
   Google Scholar
• SILBERSTEIN SD, STARK SR, LUCAS SM, CHRISTIE SN, DEGRYSE RE, TURKEL CC: Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Mayo Clin. Proc. (2005) 80:1126-1137.
   PubMed Web of Science ®Google Scholar
• MATHEW NT, FRISHBERG BM, GAWEL M, DIMITROVA R, GIBSON J, TURKEL C: Botulinum toxin type A (BOTOX) for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial. Headache (2005) 45:293-307.
   PubMed Web of Science ®Google Scholar
• OLESEN J, BOUSSER MG, DIENER HC et al.: New appendix criteria open for a broader concept of chronic migraine. Cephalalgia (2006) 26:742-746.
   PubMed Web of Science ®Google Scholar
• DODICK DW, MAUSKOP A, ELKIND AH, DEGRYSE R, BRIN MF, SILBERSTEIN SD: Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study. Headache (2005) 45:315-324.
   PubMed Web of Science ®Google Scholar
• EDVINSSON L, EKMAN R, JANSEN I, MCCULLOCH J, UDDMAN R: Calcitonin gene-related peptide and cerebral blood vessels: distribution and vasomotor effects. J. Cereb. Blood Flow Metab. (1987) 7:720-728.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ: Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. Drugs (2005) 65:2557-2567.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L, EKMAN R: Release of vasoactive peptides in the extracerebral circulation of man and the cat during activation of the trigeminovascular system. Ann. Neurol. (1988) 23:193-196.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L, EKMAN R: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann. Neurol. (1990) 28:183-187.
   PubMed Web of Science ®Google Scholar
• GALLAI V, SARCHIELLI P, FLORIDI A et al.: Vasoactive peptides levels in the plasma of young migraine patients with and without aura assessed both interictally and ictally. Cephalalgia (1995) 15:384-390.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L: Human in vivo evidence for trigeminovascular activation in cluster headache. Brain (1994) 117:427-434.
   PubMed Web of Science ®Google Scholar
• FANCIULLACCI M, ALESSANDRI M, FIGINI M, GEPPETTI P, MICHELACCI S: Increase in plasma calcitonin gene-related peptide from extracerebral circulation during nitroglycerin-induced cluster headache attack. Pain (1995) 60:119-123.
   PubMed Web of Science ®Google Scholar
• TVEDSKOV JF, LIPKA K, ASHINA M, IVERSEN HK, SCHIFTER S, OLESEN J: No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann. Neurol. (2005) 58:561-568.
   PubMed Web of Science ®Google Scholar
• MAY A, GOADSBY PJ: Substance P receptor antagonists in the therapy of migraine. Expert Opin. Investig. Drugs (2001) 10:1-6.
   PubMed Web of Science ®Google Scholar
• THOMSEN LL, KRUUSE C, IVERSEN HK, OLESEN J: A nitric oxide donor (nitroglycerine) triggers genuine migraine attacks. Eur. J. Neurol. (1994) 1:73-80.
   PubMed Web of Science ®Google Scholar
• AFRIDI S, KAUBE H, GOADSBY PJ: Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain (2004) 110:675-680.
   PubMed Web of Science ®Google Scholar
• JUHASZ G, ZSOMBOK T, MODOS EA et al.: NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain (2003) 106:461-470.
   PubMed Web of Science ®Google Scholar
• BUZZI MG, MOSKOWITZ MA, SHIMIZU T, HEATH HH: Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology (1991) 30:1193-1200.
   PubMed Web of Science ®Google Scholar
• ARVIEU L, MAUBORGNE A, BOURGOIN S et al.: Sumatriptan inhibits the release of CGRP and substance P from the rat spinal cord. Neuroreport (1996) 7:1973-1976.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L: Peripheral and central trigeminovascular activation in cat is blocked by the serotonin (5HT)-1D receptor agonist 311C90. Headache (1994) 34:394-399.
   PubMed Web of Science ®Google Scholar
• GOADSBY PJ, EDVINSSON L: The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann. Neurol. (1993) 33:48-56.
   PubMed Web of Science ®Google Scholar
• ZAGAMI AS, GOADSBY PJ, EDVINSSON L: Stimulation of the superior sagittal sinus in the cat causes release of vasoactive peptides. Neuropeptides (1990) 16:69-75.
   PubMed Web of Science ®Google Scholar
• KNIGHT YE, EDVINSSON L, GOADSBY PJ: Blockade of CGRP release after superior sagittal sinus stimulation in cat: a comparison of avitriptan and CP122,288. Neuropeptides (1999) 33:41-46.
   PubMed Web of Science ®Google Scholar
• KNIGHT YE, EDVINSSON L, GOADSBY PJ: 4991W93 inhibits release of calcitonin gene-related peptide in the cat but only at doses with 5HT1B/1D receptor agonist activity. Neuropharmacology (2001) 40:520-525.
   PubMed Web of Science ®Google Scholar
• DURHAM PL, SHARMA RV, RUSSO AF: Repression of the calcitonin gene-related peptide promoter by 5-HT1 receptor activation. J. Neurosci. (1997) 17:9545-9553.
   PubMed Web of Science ®Google Scholar
• DURHAM PL, RUSSO AF: Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J. Neurosci. (1999) 19:3423-3429.
   PubMed Web of Science ®Google Scholar
• BELLAMY J, BOWEN EJ, RUSSO AF, DURHAM PL: Nitric oxide regulation of calcitonin gene-related peptide gene expression in rat trigeminal ganglia neurons. Eur. J. Neurosci. (2006) 23:2057-2066.
   PubMed Web of Science ®Google Scholar
• DOODS H, HALLERMAYER G, WU D et al.: Pharmacological profile of BIBN-4096-BS, the first selective small molecule CGRP antagonist. Br. J. Pharmacol. (2000) 129:420-423.
   PubMed Web of Science ®Google Scholar
• MORENO MJ, ABOUNADER R, HEBERT E, DOODS H, HAMEL E: Efficacy of the non-peptide CGRP receptor antagonist BIBN-4096-BS in blocking CGRP-induced dilations in human and bovine cerebral arteries: potential implications in acute migraine treatment. Neuropharmacology (2002) 42:568-576.
   PubMed Web of Science ®Google Scholar
• PETERSEN KA, LASSEN LH, BIRK S, OLESEN J: The effect of the nonpeptide CGRP-antagonist, BIBN406BS on human-alphaCGRP induced headache and hemodynamics in healthy volunteers. Cephalalgia (2003) 23:725.
   Google Scholar
• STORER RJ, AKERMAN S, GOADSBY PJ: Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br. J. Pharmacol. (2004) 142:1171-1181.
   PubMed Web of Science ®Google Scholar
• OLESEN J, DIENER H-C, HUSSTEDT I-W et al.: Calcitonin gene-related peptide (CGRP) receptor antagonist BIBN-4096-BS is effective in the treatment of migraine attacks. N. Engl. J. Med. (2004) 350:1104-1110.
   PubMed Web of Science ®Google Scholar
• PETERSEN KA, BIRK S, LASSEN LH, KRUUSE C, JONASSEN O, OLESEN J: The novel CGRP-antagonist, BIBN-4096-BS does not affect the cerebral hemodynamics in healthy volunteers. Cephalalgia (2003) 23:729.
   Google Scholar
• FERRARI MD; THE SUBCUTANEOUS SUMATRIPTAN INTERNATIONAL STUDY GROUP: Treatment of migraine attacks with sumatriptan. N. Engl. J. Med. (1991) 325:316-321.
   PubMed Web of Science ®Google Scholar
• WILLIAMS TM, STUMP CA, NGUYEN DN et al.: Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead. Bioorg. Med. Chem. Lett. (2006) 16:2595-2598.
   PubMed Web of Science ®Google Scholar
• CATERINA MJ, SCHUMACHER MA, TOMINAGA M, ROSEN TA, LEVINE JD, JULIUS D: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature (1997) 389:816-824.
   PubMed Web of Science ®Google Scholar
• JOO F, SZOLCSANYI J, JANCSO-GABOR A: Mitochondrial alterations in the spinal ganglion cells of the rat accompanying the long-lasting sensory disturbance induced by capsaicin. Life Sci. (1969) 8:621-626.
   PubMed Web of Science ®Google Scholar
• GUO A, VULCHANOVA L, WANG J, LI X, ELDE R: Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur. J. Neurosci. (1999) 11:946-958.
   PubMed Web of Science ®Google Scholar
• ICHIKAWA H, SUGIMOTO T: VR1-immunoreactive primary sensory neurons in the rat trigeminal ganglion. Brain Res. (2001) 890:184-188.
   PubMed Web of Science ®Google Scholar
• MARKOWITZ S, SAITO K, MOSKOWITZ MA: Neurogenically mediated leakage of plasma proteins occurs from blood vessels in dura mater but not brain. J. Neurosci. (1987) 7:4129-4136.
   PubMed Web of Science ®Google Scholar
• HOU M, UDDMAN R, TAJTI J, KANJE M, EDVINSSON L: Capsaicin receptor immunoreactivity in the human trigeminal ganglion. Neurosci. Lett. (2002) 330:223-226.
   PubMed Web of Science ®Google Scholar
• AKERMAN S, KAUBE H, GOADSBY PJ: Vanilloid type 1 receptor (VR1) evoked CGRP release plays a minor role in causing dural vessel dilation via the trigeminovascular system. Br. J. Pharmacol. (2003) 140:718-724.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON DJ, HARGREAVES RJ, HILL RG, SHEPHEARD SL: Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat- intravital microscope studies. Cephalalgia (1997) 17:525-531.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON DJ, HARGREAVES RJ, HILL RG, SHEPHEARD SL: Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural blood vessel diameter in the anaesthetized rat. Cephalalgia (1997) 17:518-524.
   PubMed Web of Science ®Google Scholar
• SHEPHEARD SL, WILLIAMSON DJ, BEER MS, HILL RG, HARGREAVES RJ: Differential effects of 5-HT1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology (1997) 36:525-533.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON DJ, SHEPHEARD SL, HILL RG, HARGREAVES RJ: The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur. J. Pharmacol. (1997) 328:61-64.
   PubMed Web of Science ®Google Scholar
• RAMI HK, THOMPSON M, STEMP G et al.: Discovery of SB-705498: a potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg. Med. Chem. Lett. (2006) 16:3287-3291.
   PubMed Web of Science ®Google Scholar
• THOMSEN LL, OLESEN J: Nitric oxide in primary headaches. Curr. Opin. Neurol. (2001) 14:315-321.
   PubMed Web of Science ®Google Scholar
• THOMSEN LL, OLESEN J: A pivotal role of nitric oxide in migraine pain. Ann. NY Aacd. Sci. (1997) 835:363-372.
   PubMed Web of Science ®Google Scholar
• OLESEN J, THOMSEN LL, LASSEN LH, OLESEN IJ: The nitric oxide hypothesis of migraine and other vascular headaches. Cephalalgia (1995) 15:94-100.
   PubMed Web of Science ®Google Scholar
• IVERSEN HK, OLESEN J, TFELT-HANSEN P: Intravenous nitroglycerin as an experimental headache model. Basic characteristics. Pain (1989) 38:17-24.
   PubMed Web of Science ®Google Scholar
• GIFFIN NJ, RUGGIERO L, LIPTON RB et al.: Premonitory symptoms in migraine: an electronic diary study. Neurology (2003) 60:935-940.
   PubMed Web of Science ®Google Scholar
• KRUUSE C, THOMSEN LL, BIRK S, OLESEN J: Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain (2003) 126:241-247.
   PubMed Web of Science ®Google Scholar
• REUTER U, BOLAY H, JANSEN-OLESEN I et al.: Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain (2001) 124:2490-2502.
   PubMed Web of Science ®Google Scholar
• HOSKIN KL, BULMER DCE, GOADSBY PJ: Fos expression in the trigeminocervical complex of the cat after stimulation of the superior sagittal sinus is reduced by L-NAME. Neurosci. Lett. (1999) 266:173-176.
   PubMed Web of Science ®Google Scholar
• DE ALBA J, CLAYTON NM, COLLINS SD, COLTHUP P, CHESSELL I, KNOWLES RG: GW-274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic effects in rat models of inflammatory and neuropathic pain. Pain (2006) 120:170-181.
   PubMed Web of Science ®Google Scholar
• BERGEROT A, HOLLAND PR, AKERMAN S et al.: Animal models of migraine. Looking at the component parts of a complex disorder. Eur. J. Neurosci. (2006) (In Press).
   PubMedGoogle Scholar
• LASSEN LH, ASHINA M, CHRISTIANSEN I, ULRICH V, OLESEN J: Nitric oxide synthesis inhibition in migraine. Lancet (1997) 349:401-402.
   PubMed Web of Science ®Google Scholar
• ALDERTON WK, ANGELL AD, CRAIG C et al.: GW-274150 and GW-273629 are potent and highly selective inhibitors of inducible nitric oxide synthase in vitro and in vivo. Br. J. Pharmacol. (2005) 145:301-312.
   PubMed Web of Science ®Google Scholar
• THOMPSON T, EVANS W: Paradoxical embolism. QJM (1930) 23:135-152.
   Google Scholar
• HAGEN PT, SCHOLZ DG, EDWARDS WD: Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. Mayo Clin. Proc. (1984) 59:17-20.
   PubMed Web of Science ®Google Scholar
• ANZOLA GP, MAGONI M, GUINDANI M, ROZZINI L, DALLA VOLTA G: Potential source of cerebral embolism in migraine with aura: a transcranial Doppler study. Neurology (1999) 52:1622-1625.
   PubMed Web of Science ®Google Scholar
• WILMSHURST P, PEARSON M, NIGHTINGALE S: Re-evaluation of the relationship between migraine and persistent foramen ovale and other right-to-left shunts. Clin. Sci. (Lond.) (2005) 108:365-367.
   PubMed Web of Science ®Google Scholar
• WILMSHURST P, NIGHTINGALE S: Relationship between migraine and cardiac and pulmonary right-to-left shunts. Clin. Sci. (2001) 100:215-220.
   PubMed Web of Science ®Google Scholar
• WILMSHURST PT, NIGHTINGALE S, WALSH KP, MORRISON WL: Effect on migraine of closure of cardiac right-to-left shunts to prevent recurrence of decompression illness or stroke or for haemodynamic reasons. Lancet (2000) 356:1648-1651.
   PubMed Web of Science ®Google Scholar
• DOWSON AJ, WILMSHURST P, MUIR KW, MULLEN M, NIGHTINGALE S; MIST STUDY INVESTIGATORS: A propsective, multicentre, double-blind, placebo-controlled study to evaluate the efficacy of patent foramen ovale closure for the resolution of refractory migraine headache (the MIST Study): prevalence and size of shunts. Headache Care (2005) 2:223-227.
   Google Scholar
• WEINER RL, REED KL: Peripheral neurostimulation for control of intractable occipital neuralgia. Neuromodulation (1999) 2:217-222.
   PubMed Web of Science ®Google Scholar
• MATHARU MS, BARTSCH T, WARD N, FRACKOWIAK RSJ, WEINER RL, GOADSBY PJ: Central neuromodulation in chronic migraine patients with suboccipital stimulators: a PET study. Brain (2004) 127:220-230.
   PubMed Web of Science ®Google Scholar
• DODICK DW, TRENTMAN T, ZIMMERMAN R, EROSS EJ: Occipital nerve stimulation for intractable chronic primary headache disorders. Cephalalgia (2003) 23:701.
   Web of Science ®Google Scholar
• GOADSBY PJ, DODICK D, MITSIAS P et al.: ONSTIM: occipital nerve stimulation for the treatment of chronic migraine. Eur. J. Neurol. (2005) 12(Suppl. 2):198.
   Google Scholar
• SILBERSTEIN SD: The US Headache Consortium Report of the Quality Standards Subcommittee of the American Academy of Neurology Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Neurology (2000) 55:754-763.
   PubMed Web of Science ®Google Scholar
• SMITH TR, SUNSHINE A, STARK SR, LITTLEFIELD DE, SPRUILL SE, ALEXANDER WJ: Sumatriptan and naproxen sodium for the acute treatment of migraine. Headache (2005) 45:983-991.
   PubMed Web of Science ®Google Scholar